These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 6309462)

  • 1. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women.
    Wall ME; Sadler BM; Brine D; Taylor H; Perez-Reyes M
    Clin Pharmacol Ther; 1983 Sep; 34(3):352-63. PubMed ID: 6309462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The metabolism of delta 9-tetrahydrocannabinol and related cannabinoids in man.
    Wall ME; Perez-Reyes M
    J Clin Pharmacol; 1981; 21(S1):178S-189S. PubMed ID: 6271823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal Physiologically Based Pharmacokinetic Model of Intravenously and Orally Administered Delta-9-Tetrahydrocannabinol in Healthy Volunteers.
    Wolowich WR; Greif R; Kleine-Brueggeney M; Bernhard W; Theiler L
    Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):691-711. PubMed ID: 31114948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex difference in the oxidative metabolism of delta 9-tetrahydrocannabinol in the rat.
    Narimatsu S; Watanabe K; Yamamoto I; Yoshimura H
    Biochem Pharmacol; 1991 Apr; 41(8):1187-94. PubMed ID: 1848985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative pharmacology of Delta9-tetrahydrocannabinol and its metabolite, 11-OH-Delta9-tetrahydrocannabinol.
    Lemberger L; Martz R; Rodda B; Forney R; Rowe H
    J Clin Invest; 1973 Oct; 52(10):2411-7. PubMed ID: 4729039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human urinary excretion profile after smoking and oral administration of [14C]delta 1-tetrahydrocannabinol.
    Johansson E; Gillespie HK; Halldin MM
    J Anal Toxicol; 1990; 14(3):176-80. PubMed ID: 2165199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex differences in Δ(9)-tetrahydrocannabinol metabolism and in vivo pharmacology following acute and repeated dosing in adolescent rats.
    Wiley JL; Burston JJ
    Neurosci Lett; 2014 Jul; 576():51-5. PubMed ID: 24909619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking.
    Ohlsson A; Lindgren JE; Wahlen A; Agurell S; Hollister LE; Gillespie HK
    Clin Pharmacol Ther; 1980 Sep; 28(3):409-16. PubMed ID: 6250760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary excretion half-life of delta 1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking.
    Johansson E; Halldin MM
    J Anal Toxicol; 1989; 13(4):218-23. PubMed ID: 2550702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man.
    Hunt CA; Jones RT; Herning RI; Bachman J
    J Pharmacokinet Biopharm; 1981 Jun; 9(3):245-60. PubMed ID: 6270295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A vapourized Δ(9)-tetrahydrocannabinol (Δ(9)-THC) delivery system part I: development and validation of a pulmonary cannabinoid route of exposure for experimental pharmacology studies in rodents.
    Manwell LA; Charchoglyan A; Brewer D; Matthews BA; Heipel H; Mallet PE
    J Pharmacol Toxicol Methods; 2014; 70(1):120-7. PubMed ID: 24973534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disposition and bioavailability of various formulations of tetrahydrocannabinol in the rhesus monkey.
    Perlin E; Smith CG; Nichols AI; Almirez R; Flora KP; Cradock JC; Peck CC
    J Pharm Sci; 1985 Feb; 74(2):171-4. PubMed ID: 2985774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and Verification of a Linked
    Patilea-Vrana GI; Unadkat JD
    Drug Metab Dispos; 2021 Jul; 49(7):509-520. PubMed ID: 33952608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic disposition of delta 8-tetrahydrocannabinol and its active metabolites, 11-hydroxy-delta 8-tetrahydrocannabinol and 11-oxo-delta 8-tetrahydrocannabinol, in mice.
    Watanabe K; Yamamoto I; Oguri K; Yoshimura H
    Drug Metab Dispos; 1981; 9(3):261-4. PubMed ID: 6113937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of reinforcing and aversive effects of voluntary Δ
    Barrus DG; Lefever TW; Wiley JL
    Neuropharmacology; 2018 Jul; 137():133-140. PubMed ID: 29758385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism of n-hexyl-homologues of delta-8-tetrahydrocannabinol and delta-9-tetrahydrocannabinol in the mouse.
    Brown NK; Harvey DJ
    Eur J Drug Metab Pharmacokinet; 1988; 13(3):165-76. PubMed ID: 2853671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterizing and Quantifying Extrahepatic Metabolism of (-)-Δ
    Kumar AR; Patilea-Vrana GI; Anoshchenko O; Unadkat JD
    Drug Metab Dispos; 2022 Jun; 50(6):734-740. PubMed ID: 35370140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma and brain levels of delta 6-THC and seven monooxygenated metabolites correlated to the cataleptic effect in the mouse.
    Ohlsson A; Widman M; Carlsson S; Ryman T; Strid C
    Acta Pharmacol Toxicol (Copenh); 1980 Oct; 47(4):308-17. PubMed ID: 6258385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Pharmacokinetics of Δ
    Torrens A; Roy P; Lin L; Vu C; Grimes D; Inshishian VC; Montesinos JS; Ahmed F; Mahler SV; Huestis MA; Das A; Piomelli D
    Cannabis Cannabinoid Res; 2022 Dec; 7(6):814-826. PubMed ID: 35353551
    [No Abstract]   [Full Text] [Related]  

  • 20. Penetration of delta-9-tetrahydrocannabinol and 11-OH-delta-9-tetrahydrocannabinol through the blood-brain barrier.
    Schou J; Prockop LD; Dahlstrom G; Rohde C
    Acta Pharmacol Toxicol (Copenh); 1977 Jul; 41(1):33-8. PubMed ID: 578377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.